Ranibizumab: A review of its use in the treatment of neovascular age-related macular degeneration

Drugs and Aging

Volumn 30, Issue 5, 2013, Pages 331-358

  Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN 121; VASCULOTROPIN 165; VERTEPORFIN;

BINDING COMPETITION; BLURRED VISION; CATARACT; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; COMPETITIVE INHIBITION; CONJUNCTIVAL HEMORRHAGE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE IRRITATION; EYE PAIN; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INJECTION; INTRAOCULAR PRESSURE; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; REVIEW; RISK REDUCTION; SIDE EFFECT; STEADY STATE; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; THROMBOEMBOLISM; VISUAL ACUITY; VITREOUS BODY DETACHMENT;

EID: 84876916993     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0077-9     Document Type: Review

References (127)

1. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs. 2008;68(8):1029-36. (Pubitemid 351693673)
2. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39(5):367-74.
3. de Jong PTVM. Age-related macular degeneration. N Engl J Med. 2006;355:1474-85. (Pubitemid 44511562)
4. Cook HL, Patel PJ, Tufail A. Age-related macular degeneration: diagnosis and management. Br Med Bull. 2008;85:127-49. (Pubitemid 351398300)
5. Waisbourd M, Loewenstein A, Goldstein M, et al. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging. 2007;24(8):643-62.
6. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77-88.
7. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005;109(3):227-41. (Pubitemid 41337127)
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76. (Pubitemid 36749215)
9. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006;90:1542-7. (Pubitemid 44862578)
10. Kovach JL, Schwartz SG, Flynn HW, Jr., et al. Anti-VEGF treatment strategies for wet AMD. J Ophthalmol. 2012;2012:786870 [online]. Available from URL: http://www.hindawi.com/journals/jop/2012/786870/ [Accessed 23 Jan 2013].
11. Lally DR, Gerstenblith AT, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2012;23(3):182-8.
12. Vedula SS, Krzystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2008;(2):CD005139.
13. Khandhadia S, Cherry J, Lotery AJ. Age-related macular degeneration. Adv Exp Med Biol. 2012;724:15-36.
14. Folk JC, Stone EM. Ranibizumab therapy for neovascular age-related macular degeneration. N Engl J Med. 2010;363(17):1648-55.
15. Blick SKA, Keating GM, Wagstaff AJ. Ranibizumab. Drugs. 2007;67(8):1199-206. (Pubitemid 46871027)
16. Lucentis 10 mg/ml solution for injection. EU summary of product characteristics. Horsham, UK: Novartis Europharm Limited [online]. Available from URL: http://www.medicines.org.uk [Accessed 2012 Sep 18].
17. Lucentis® (ranibizumab injection). US prescribing information. South San Francisco (CA): Genentech Inc. [online]. Available from URL: http://www.lucentis.com [Accessed 2012 Sep 18].
18. Vinores SA. Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomed. 2006;1(3):263-8.
19. Frampton JE. Aflibercept for intravitreal injection: in neovascular age-related macular degeneration. Drugs Aging. 2012;29(10):839-46.
20. Pitlick JM, Vecera KF, Barnes KN, et al. Bevacizumab for the treatment of neovascular age-related macular degeneration. Ann Pharmacother. 2012;46(2):290-6.
21. Brechner RJ, Rosenfeld PJ, Babish JD, et al. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol. 2011;151(5):887-95.e1.
22. Ziemsson F, Grisanti S, Bartz-Schmidt KU, et al. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs Aging. 2009;26(4):295-320.
23. Frampton JE. Ranibizumab: in diabetic macular oedema. Drugs. 2012;72(4):509-23.
24. Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85(4):425-30. (Pubitemid 47542265)
25. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859-70. (Pubitemid 44547437)
26. Carneiro A, Falcão M, Pirraco A, et al. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res. 2009;88(3):522-7.
27. Costa R, Carneiro A, Rocha A, et al. Bevacizumab and ranibizumab on microvascular endothelial cells: a comparative study. J Cell Biochem. 2009;108(6):1410-7.
28. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171-85.
29. Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun. 2011;408(2):276-81.
30. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49:4523-7.
31. Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol. 2007;245:1837-42. (Pubitemid 350154019)
32. Muether P, Hermann MM, Viebahn U, et al. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology. 2012;119(10):2082-6.
33. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-44. (Pubitemid 44511558)
34. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.
35. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31. (Pubitemid 44511557)
36. Sadda SR, Stoller G, Boyer DS, et al. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year ANCHOR study. Retina. 2010;30(9):1390-9.
37. Kaiser PK, Blodi BA, Shapiro H, et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(10):1868-75.e4.
38. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116(9):1731-9.
39. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897- 908.
40. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two year results. Ophthalmology. 2012;119(7):1388-98.
41. Chakravarty U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399-411.
42. Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol (Oxf). 2012;90(1):e25-30.
43. Center for Drug Evaluation and Research. BLA application number: 125156. Clinical Pharmacology and Biopharmaceutics review(s) [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2006/125156s0000- Lucentis-ClinPharmR.pdf [Accessed 2012 Jul 1].
44. Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154(4):682-6.
45. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144(6):850-7. (Pubitemid 350130239)
46. Bressler NM, Chang TS, Fine JT, et al. Improved vision-related function after ranibizumab vs. photodynamic therapy: a randomized clinical trial. Arch Ophthalmol. 2009;127(1):13-21.
47. Bressler NM, Chang TS, Varma R, et al. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. Ophthalmology. 2013;120(1):160-8.
48. Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012;119(5):1001-10.
49. Novartis. Verteporfin photodynamic therapy administered in conjunction with ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) [ClinicalTrials.gov identifier NCT00433017]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00433017 [Accessed 2012 Jul 27].
50. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831-9.
51. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 2006;124(11):1532-42. (Pubitemid 44748725)
52. Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145(5):862-74.
53. Genentech. A study of ranibizumab administered monthly or on an as-needed basis in patients with subfoveal neovascular age-related macular degeneration (HARBOR) [ClinicalTrials.gov identifier NCT00891735]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials. gov/ct2/show/NCT00891735 [Accessed 2012 Jul 1].
54. Suner IJ, Yau L, Lai P. HARBOR study: one-year results of efficacy and safety of 2.0 mg versus 0.5 mg ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration [abstract no. 3677]. Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale; May 6-10 2011.
55. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175-83.
56. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246-52. (Pubitemid 46172497)
57. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125(11):1460-9. (Pubitemid 350106676)
58. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular generation: twelve-month MONT BLANC study results. Ophthalmology. 2012;19(5):992-1000.
59. Novartis. Efficacy/safety of verteporfin photodynamic therapy and ranibizumab compared with ranibizumab in patients with subfoveal choroidal neovascularization [ClinicalTrials.gov identifier NCT00436553]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00436553 [Accessed 2012 Jul 27].
60. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145(2):239-48.
61. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150(3):315-24.e1.
62. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566-83. (Pubitemid 46452533)
63. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58.e1.
64. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-48.
65. Regeneron Pharmaceuticals, Inc. Two year results of phase 3 studies with EYLEA™ (aflibercept) injection in wet AMD show sustained improvement in visual acuity [media release]. Dec 5 2011. Available from URL: http://investor.regeneron.com [Accessed 2012 Oct 17].
66. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4):663-71.
67. Silva R, Axer-Siegel R, Eldem B, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):130-9.
68. Cunningham ET Jr, Feiner L, Chung C, et al. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. Ophthalmology. 2011;118(12):2447-52.
69. Barbazetto I, Saroj N, Shapiro H, et al. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. Retina. 2010;30(9):1376-85.
70. Ladas ID, Karagiannis DA, Rouvas A, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2000 injections. Retina. 2009;29:313-8.
71. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab or ranibizumab. Retina. 2008;28(10):1395-9.
72. Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028-34.
73. Bressler NM, Boyer DS, Williams DF, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina. 2012;32(9):1821-8.
74. European Medicines Agency. Assessment report. Eylea aflibercept. Procedure No.: EMEA/H/C/002392/ [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/002392/WC500135744.pdf [Accessed 2013 Jan 25].
75. Athanasakis K, Fragoulakis V, Tsiantou V, et al. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece. Clin Ther. 2012;34(2):446-56.
76. Brown MM, Brown GC, Brown HC, et al. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology. 2008;115(6):1039-45.e5.
77. Nwanze CC, Akinwale A, Adelman RA. Bevacizumab vs. ranibizumab in preserving or improving vision in patients with wet, age-related macular degeneration: a cost-effectiveness review. Clin Med Insights Ther. 2012;4:29-38.
78. Colquitt JL, Jones J, Tan SC, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2008;12(16):iii-iv, ix-201.
79. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, et al. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010;248(4):467-76.
80. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc. 2008;6:12 [online]. Available from URL: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2443361/ [Accessed 2012 Nov 30].
81. Neubauer AS, Holz FG, Sauer S, et al. Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: model analysis from the perspective of Germany's statutory health insurance system. Clin Ther. 2010;32(7):1343-56.
82. Canadian Agency for Drugs and Technologies in Health. Common drug review: ranibizumab (Lucentis® - Novartis Pharmaceuticals Canada Inc.). Indication: age-related macular degeneration (AMD). Overview of CDR clinical and pharmacoeconomic reports August 2008. Ottawa (ON): CADTH, 2008 [online]. Available from URL: http://www.cadth.ca/media/cdr/relatedinfo/cdr-trans- Lucentis-overview-Jul-30-08-e.pdf [Accessed 2012 Sep 20].
83. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, et al. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. Clin Ther. 2008;30(12):2436-51.
84. Cohen SY, Bremond-Gignac D, Quentel G, et al. Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2008;246(11):1527-34.
85. Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol. 2007;91(9):1244-6. (Pubitemid 47344908)
86. Patel JJ, Mendes MAS, Bounthavong M, et al. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. J Eval Clin Pract. 2012;18(2):247-55.
87. Kaiser PK, for the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol. 2006;244:1132-42. (Pubitemid 44269592)
88. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-16. (Pubitemid 40051904)
89. Casten R, Rovner B. Depression in age-related macular degeneration. J Vis Impair Blind. 2008;102(10):591-9.
90. Dhoot DS, Kaiser PK. Ranibizumab for age-related macular degeneration. Expert Opin Biol Ther. 2012;12(3):371-81.
91. Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011;129(6):709-17.
92. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94(1):2-13.
93. Kumar A, Sahni JN, Stangos AN, et al. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. Br J Ophthalmol. 2011;95(4):530-3.
94. Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol. 2010;94(3):292-6.
95. Rothenbuehler SP, Waeber D, Brinkmann CK, et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol. 2009;147(5):831-7.
96. Bandukwala T, Muni RH, Schwartz C, et al. Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review. Can J Ophthalmol. 2010;45(6):590-5.
97. Katz G, Giavedoni L, Muni R, Evans T, et al. Effectiveness at 1 year of monthly versus variable-dosing intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2012;32(2):293-8.
98. Hjelmquist L, Lindberg C, Kanulf P, et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol. 2011;2011:405724 [online]. Available from URL: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3228303/ [Accessed 2013 Jan 25].
99. Heimes B, Lommatzsch A, Zeimer M, et al. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol. 2011;249(5):639-44.
100. Wykoff CC, Brown DM. Controversies in the treatment of AMD [online]. Available from URL: http://www.medscape.org/viewarticle/765080 [Accessed 2012 Oct 11].
101. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143(4):679-80. (Pubitemid 46452536)
102. Toalster N, Russell M, Ng P. 12-month results of a treat and extend variable dosing-frequency regime for ranibizumab treatment of exudative age-related macular degeneration [abstract]. Graefes Arch Clin Exp Ophthalmol. 2011;39:70.
103. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina. 2011;31(1):26-30.
104. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117(11):2134-40.
105. Krüger Falk M, Kemp H, Sørensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol. 2013;155:89-95.
106. Pushpoth S, Sykakis E, Merchant K, et al. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol. 2012;96(12):1469-73.
107. Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf. 2010;9(1):149-65.
108. Mojica G, Hariprasad SM, Jager RD, et al. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration [abstract]. Br J Ophthalmol. 2008;92(4):584.
109. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol. 2010;128(12):1523-7.
110. Sharei V, Höhn F, Köhler T, et al. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010;20(1):174-9.
111. Semeraro F, Morescalchi F, Parmeggiani F, et al. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. Curr Vasc Pharmacol. 2011;9(5):629-46.
112. Koh AH, Lee WK, Chen LJ, et al. EVEREST STUDY: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453-64.
113. Ziemssen F, Sobolewska B. Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management? Drugs Aging. 2011;28:853-65.
114. Lotery A. CATT Meet IVAN. What have we learned from the ongoing ranibizumab vs bevacizumab trials? Retinal Physician. 2012;9:25-7.
115. Kaiser PK, Cruess AF, Bogaert P, et al. Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicenced medicines. Graefes Arch Clin Exp Ophthalmol. 2012;250:1563-71.
116. Hospices Civils de Lyon. French Evaluation Group Avastin Versus Lucentis (GEFAL) [ClinicalTrials.gov identifier NCT01170767]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials. gov/ct2/show/NCT01170767 [Accessed 2012 Jul 1].
117. Klinikum Bremen-Mitte GmbH. Prevention of vision loss in patients with age-related macular degeneration (AMD) by intravitreal injection of bevacizumab and ranibizumab (VIBERA) [ClinicalTrials.gov identifier NCT00559715]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00559715 [Accessed 2012 Jul 1].
118. The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery. Manta study: Avastin versus Lucentis in age related macular degeneration (MANTA) [ClinicalTrials.gov identifier NCT00710229]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00710229 [Accessed 2012 Jul 1].
119. Academic Medical Center (AMC), Department of Ophtalmology. Comparison of bevacizumab (Avastin) and ranibizumab (Lucentis) in exudative age-related macular degeneration [Nederlands Trial Register number NTR1704]. Netherlands National Trial Register, trialregister.nl [online]. Available from URL: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1704 [Accessed 2012 Dec 7].
120. Ullevaal University Hospital. LUCAS (Lucentis compared to Avastin Study [ClinicalTrials.gov identifier NCT01127360]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/ show/NCT01127360 [Accessed 2012 Dec 7].
121. AMD Alliance International. AMD Alliance International responds to CATT trials research [online]. Available from URL: http://www.amdalliance.org/AMDAI- CATT-Response.html [Accessed 2012 Oct 10].
122. Sharma S, Johnson D, Abouammoh M, et al. Rate of serious adverse events in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol. 2012;47(3):275-9.
123. American Academy of Ophthalmology. Age-related macular degeneration summary benchmarks for preferred practice pattern® guidelines [online]. Available from URL: http://www.aao.org [Accessed 2012 Oct 15].
124. The Royal College of Ophthalmologists. Age-related macular degeneration. Guidelines for management [online]. Available from URL: http://www.rcophth.ac.uk [Accessed 2012 Oct 15].
125. EYLEA™ (aflibercept) injection: US prescribing information. Tarrytown (NY); Regeneron Pharmaceuticals, Inc. [online]. Available from URL: http://www.regeneron.com/Eylea/eylea-fpi.pdf [Accessed 2012 Apr 2].
126. Mitchell P, Annemans L, White R. Cost effectiveness of treatments for wet age-related macular degeneration. Pharmacoeconomics. 2011;29:107-31.
127. Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Research 2010;10:10 [online]. Available from URL: http://www.biomedcentral.com/content/pdf/1472-6963-10-153.pdf [Accessed 2012 Oct 17].